MGX (Metagenomi) Other Long-Term Liabilities : $2.11 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Metagenomi Other Long-Term Liabilities?

Metagenomi's other long-term liabilities for the quarter that ended in Mar. 2025 was $2.11 Mil.

Metagenomi's quarterly other long-term liabilities declined from Sep. 2024 ($3.08 Mil) to Dec. 2024 ($2.01 Mil) but then increased from Dec. 2024 ($2.01 Mil) to Mar. 2025 ($2.11 Mil).

Metagenomi's annual other long-term liabilities increased from Dec. 2022 ($347.14 Mil) to Dec. 2023 ($355.84 Mil) but then declined from Dec. 2023 ($355.84 Mil) to Dec. 2024 ($2.01 Mil).

Metagenomi Other Long-Term Liabilities Historical Data

The historical data trend for Metagenomi's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Metagenomi Other Long-Term Liabilities Chart

Metagenomi Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

76.50

347.14

355.84

2.01

Metagenomi Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Long-Term Liabilities	Get a 7-Day Free Trial							5.08	3.80	3.08	2.01	2.11

Metagenomi Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Metagenomi Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Metagenomi's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Metagenomi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metagenomi Inc (NAS:MGX) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608

Website

https://metagenomi.co

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.